Free Newsletter
Grassley asks AMA, others for payment data
Sen. Charles Grassley has sent letters to 33 industry groups--including the American Medical Association and American Cancer Society--requesting that the organizations reveal industry funding. The request is part of the Senate Finance Committee's ongoing probe into the influence pharma industry money may have on disease and medical advocacy organizations. "These organizations have a lot of influence over public policy, and people rely on their leadership," Grassley said in the New York Times. "There's a strong case for disclosure and the accountability that results."
The AMA, American Cancer Society and the Alzheimer's Association all said in statements that they would respond to Grassley's request for detailed payment information. The amount of money organizations accept varies widely. The AMA, for example, says that less than 2 percent of its funding comes from industry donations. But when Grassley requested industry donation data from the National Alliance on Mental Illness earlier this year, it was revealed that two-thirds of the group's budget came from industry sources. That entanglement prevented NAMI from freely addressing certain concerns it had with mental health drug safety; doing so would have jeopardized its funding.
Grassley didn't just ask these organizations about their overall funding. In the letters he also requested specific information about how much industry money is being funneled to the groups' directors--a request that's almost sure to lead to some discomfort. He has asked the organizations to respond by Dec. 21.
- a copy of Grassley's letter is available here (.pdf)
- here's the New York Times report
Related Articles:
Grassley's beat goes on with NAMI probe
Grassley asks for Pfizer-Harvard payment info
Disclosure trend hits PBM-drugmaker deals
Pharma, academia ties difficult to unwind
Comments
Not unlike the "Climategate" embarrassment, all you need to do is follow the money trail to discover the truth. I imagine much creative accounting is going on at medical societies - even as we speak! We've now learned even "experts" will lie to protect and promote their dogma.
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession





